Which company makes Seleniso?

Selinexor This emerging drug in the anti-cancer field is developed by Karyopharm Therapeutics. This biopharmaceutical company is unique in its focus on developing targeted drugs that target nuclear transport, injecting new vitality into the field of cancer treatment. In Karyopharm Therapeutics' rich R&D pipeline, drugs such as Selinexor, Verdinexor and KPT-9274 have shown great potential in the journey to conquer the disease. Especially selinexole, this drug was approved by the U.S. Food and Drug Administration (FDA) in July 2019, bringing new treatment hope to cancer patients.

The approval of selinesol was based on the positive results of the single-arm Phase IIb clinical trial. The combination with dexamethasone received accelerated approval and was granted orphan drug designation, which fully reflects its unique advantages in the treatment of certain rare or refractory cancers.

In the United States, selinesol is marketed by Karyopharm Therapeutics under the trade nameXpovio. Subsequently, in June 2020, the FDA further expanded the indications of selinesol and approved it for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is based on solid data from the SADAL trial, a multicenter, single-arm, open-label study involving patients with DLBCL who had received multiple systemic therapies.

The same yearIn December of the same year, the FDA once again expanded the indications of selinesol and approved its use in combination with bortezomib and dexamethasone, providing a new treatment option for adult patients with multiple myeloma who have received at least one treatment in the past. This series of approvals not only demonstrates the broad potential of selinesol in the anti-cancer field, but also reflects Karyopharm Therapeutics’ outstanding strength in drug research and development.